ERBB2 and neoplasm: One study demonstrated that in contrast to plasma ctDNA which showed decreasing ERBB2 levels and other tumor-specific mutations during treatment with trastuzumab emtansine, CSF ctDNA revealed continued high levels of ERBB2, MYC copy numbers, PIK3CA, and TP53 mutations, which were identified prior to the start of treatment (40).